3,920 Shares in Exact Sciences Co. (NASDAQ:EXAS) Bought by Focus Financial Network Inc.

Focus Financial Network Inc. bought a new stake in Exact Sciences Co. (NASDAQ:EXAS) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,920 shares of the medical research company’s stock, valued at approximately $267,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Exact Sciences by 16.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 89,196 shares of the medical research company’s stock valued at $6,160,000 after purchasing an additional 12,349 shares during the period. CANADA LIFE ASSURANCE Co increased its position in shares of Exact Sciences by 5.3% during the first quarter. CANADA LIFE ASSURANCE Co now owns 207,364 shares of the medical research company’s stock worth $14,361,000 after acquiring an additional 10,356 shares in the last quarter. Profund Advisors LLC increased its position in shares of Exact Sciences by 239.8% during the second quarter. Profund Advisors LLC now owns 78,589 shares of the medical research company’s stock worth $3,320,000 after acquiring an additional 55,459 shares in the last quarter. William Blair Investment Management LLC bought a new stake in Exact Sciences in the 2nd quarter valued at $163,896,000. Finally, Grandfield & Dodd LLC lifted its position in Exact Sciences by 142.5% in the 1st quarter. Grandfield & Dodd LLC now owns 55,224 shares of the medical research company’s stock valued at $3,814,000 after acquiring an additional 32,453 shares in the last quarter. 88.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on EXAS shares. Raymond James reissued a “market perform” rating on shares of Exact Sciences in a research note on Thursday, September 26th. Benchmark cut their target price on Exact Sciences from $91.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. The Goldman Sachs Group decreased their price target on shares of Exact Sciences from $88.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, July 17th. Stifel Nicolaus cut their price objective on shares of Exact Sciences from $100.00 to $82.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Finally, Evercore ISI raised their target price on shares of Exact Sciences from $72.00 to $80.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Exact Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $80.64.

Insider Activity

In related news, EVP Brian Baranick sold 929 shares of the business’s stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the transaction, the executive vice president now directly owns 12,758 shares of the company’s stock, valued at approximately $893,060. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.36% of the company’s stock.

Exact Sciences Trading Up 1.3 %

Shares of NASDAQ:EXAS opened at $69.80 on Monday. The company has a 50-day simple moving average of $66.81 and a 200 day simple moving average of $56.59. The company has a market capitalization of $12.90 billion, a P/E ratio of -72.71 and a beta of 1.27. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.98 and a current ratio of 2.17. Exact Sciences Co. has a 52-week low of $40.62 and a 52-week high of $79.62.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.